TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Pharmacotherapeutic Education on Medication Adherence and Adverse Outcomes in Type 2 Diabetes Mellitus Patients: Prospective, Randomized Study
Brief Summary: Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that affects more than 400 million people worldwide. There are a few studies evaluating ADRs in diabetics. Many patients experience ADRs soon after hospital discharge which can be attributed to the changes in the pharmacotherapy during hospitalization. Education and counseling of diabetic patients has been shown to improve medication adherence and clinical outcomes. Studies that included medical patients revealed that education can significantly reduce risk of ADRs after hospital discharge. Pharmacotherapeutic education is a part of comprehensive education of diabetics that is focused on a proper use of medications, prevention and early detection of ADRs.


Options:
A: Intervention Type: BEHAVIORAL; Name: Early hospital discharge facilitated by close nurse practitioner follow-up; Assigned to Arm(s): N/A
B: Arm Label: Follow-up phone call from Nurse; Type: EXPERIMENTAL; Interventions: Other: Phone call follow-up | Arm Label: Satisfaction survey; Type: PLACEBO_COMPARATOR; Interventions: Other: Satisfaction survey | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Control group --- no intervention | Intervention Type: OTHER; Name: Phone call follow-up; Assigned to Arm(s): Follow-up phone call from Nurse | Intervention Type: OTHER; Name: Satisfaction survey; Assigned to Arm(s): Satisfaction survey | Intervention Type: OTHER; Name: Control group --- no intervention; Assigned to Arm(s): Control group
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Intervention group
D: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftobiprole Versus Intravenous Standard-of-care Cephalosporin Treatment With or Without Vancomycin in Pediatric Patients Aged From 3 Months to Less Than 18 Years With Hospital-acquired Pneumonia or Community-acquired Pneumonia Requiring Hospitalisation
Brief Summary: This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired bacterial pneumonia (HAP) or community-acquired bacterial pneumonia (CAP) requiring hospitalization, and requiring intravenous (IV) antibiotic therapy.


Options:
A: Arm Label: Ceftobiprole medocaril; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole medocaril | Arm Label: IV standard-of-care cephalosporin; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV standard-of-care cephalosporin | Intervention Type: DRUG; Name: ceftobiprole medocaril; Assigned to Arm(s): Ceftobiprole medocaril | Intervention Type: DRUG; Name: IV standard-of-care cephalosporin; Assigned to Arm(s): IV standard-of-care cephalosporin
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
C: Arm Label: Colistin and Meropenem; Type: EXPERIMENTAL; Interventions: Drug: Colistin, Drug: Meropenem | Arm Label: Colistin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colistin | Intervention Type: DRUG; Name: Colistin; Assigned to Arm(s): Colistin, Colistin and Meropenem | Intervention Type: DRUG; Name: Meropenem; Assigned to Arm(s): Colistin and Meropenem
D: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double Blind, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Brief Summary: For hemodialysis subjects currently receiving ESAs with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.


Options:
A: Arm Label: rHuEPO or DA to ASP1517; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: rHuEPO or DA to DA; Type: EXPERIMENTAL; Interventions: Drug: DA | Arm Label: Epoetin beta pegol to ASP1517; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): Epoetin beta pegol to ASP1517, rHuEPO or DA to ASP1517 | Intervention Type: DRUG; Name: DA; Assigned to Arm(s): rHuEPO or DA to DA
B: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat TIW; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat TIW | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Alfa | Intervention Type: DRUG; Name: Vadadustat TIW; Assigned to Arm(s): Vadadustat TIW
C: Arm Label: MT-6548; Type: EXPERIMENTAL; Interventions: Drug: MT-6548, Drug: Darbepoetin alfa-matching placebo | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: MT-6548-matching placebo | Intervention Type: DRUG; Name: MT-6548; Assigned to Arm(s): MT-6548 | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: MT-6548-matching placebo; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa-matching placebo; Assigned to Arm(s): MT-6548
D: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Epoetin alfa

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
Brief Summary: The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as compared to the control group where the two HZ/su doses are administered subsequent to Prevenar13.


Options:
A: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: HZ/su vaccine GSK1437173A, Biological: Prevenar13 | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: HZ/su vaccine GSK1437173A, Biological: Prevenar13 | Intervention Type: BIOLOGICAL; Name: HZ/su vaccine GSK1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: Prevenar13; Assigned to Arm(s): Co-Ad Group, Control Group
B: Arm Label: GSK1437173A formulation 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 3 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A formulation 1 Group, GSK1437173A formulation 2 Group, GSK1437173A formulation 3 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: NBP608; Type: EXPERIMENTAL; Interventions: Biological: NBP608 | Arm Label: Zostavax; Type: ACTIVE_COMPARATOR; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: NBP608; Assigned to Arm(s): NBP608 | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Zostavax
D: Arm Label: GSK1437173A Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Assigned to Arm(s): Control Group, GSK1437173A Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Superior Venous Access, Midline vs Ultrasound IVs: A Randomized Clinical Trial
Brief Summary: Obtaining intravenous access (IVA) is the most common procedure performed in the emergency department (ED). Placement of IVA allows for blood work and delivery of intravenous fluids and medications. The implementation of ultrasound guided peripheral IVs (UGPIV) have allowed for ultrasound to be used to place an IV into patients with difficult vein access (DVA). An alternative device to place is a midline catheter (MC). The use of MCs against UGPIV has not been compared in a randomized study. Aim 1: To determine if UGPIVs have a higher failure rate than midline catheters within 72 hours of placement. Aim 2: To collect information to perform a direct cost analysis of UGPIV against that of the midline catheter. Aim 3: Assess patient satisfaction.


Options:
A: Arm Label: PICC line; Type: EXPERIMENTAL; Interventions: Device: Use of a PICC line for chemo administration (PowerPICC SOLO²) | Arm Label: Implanted Port; Type: ACTIVE_COMPARATOR; Interventions: Device: implanted port for chemo administration (X-port isp), Device: Use of a PICC line for chemo administration (PowerPICC SOLO²) | Intervention Type: DEVICE; Name: implanted port for chemo administration (X-port isp); Assigned to Arm(s): Implanted Port | Intervention Type: DEVICE; Name: Use of a PICC line for chemo administration (PowerPICC SOLO²); Assigned to Arm(s): Implanted Port, PICC line
B: Arm Label: Midline Catheter; Type: EXPERIMENTAL; Interventions: Device: Midline insertion | Arm Label: Peripheral intravenous cannulation (PIVC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Midline insertion; Assigned to Arm(s): Midline Catheter
C: Arm Label: Ultrasound Guided Peripheral IV Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Ultrasound Guided Peripheral IV Catheter | Arm Label: Midline Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Midline Catheter | Intervention Type: DEVICE; Name: Ultrasound Guided Peripheral IV Catheter; Assigned to Arm(s): Ultrasound Guided Peripheral IV Catheter | Intervention Type: DEVICE; Name: Midline Catheter; Assigned to Arm(s): Midline Catheter
D: Arm Label: Grade 1 Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 2A Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 2b Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 3 Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Intervention Type: OTHER; Name: IV placement using ultrasound guidance vs traditional method; Assigned to Arm(s): Grade 1 Vein Visualization, Grade 2A Vein Visualization, Grade 2b Vein Visualization, Grade 3 Vein Visualization

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuralgic Amyotrophy: Central Reorganization and Rehabilitation After Peripheral Dysfunction
Brief Summary: This study evaluates the effect of a specific, multidisciplinary and personalized rehabilitation program compared to usual care, on motor control and functional disability in patients with neuralgic amyotrophy.

Half of the participants will start with the 17-week specific rehabilitation program while the other half will first continue their usual care for 17 weeks, after which they will also receive the 17-week specific rehabilitation program.


Options:
A: Arm Label: Specific rehabilitation program; Type: EXPERIMENTAL; Interventions: Behavioral: Specific rehabilitation program | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Specific rehabilitation program, Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Specific rehabilitation program; Assigned to Arm(s): Specific rehabilitation program, Usual Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Feet First; Type: EXPERIMENTAL; Interventions: Behavioral: Feet First | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feet First; Assigned to Arm(s): Feet First
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Educational session to promote physical activity | Arm Label: 2; Type: OTHER; Interventions: Other: Minimal contact | Intervention Type: OTHER; Name: Educational session to promote physical activity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Minimal contact; Assigned to Arm(s): 2
D: Arm Label: Standard Care Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care Counseling | Arm Label: Supervised Exercise and Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Exercise and Counseling | Intervention Type: BEHAVIORAL; Name: Standard Care Counseling; Assigned to Arm(s): Standard Care Counseling | Intervention Type: BEHAVIORAL; Name: Supervised Exercise and Counseling; Assigned to Arm(s): Supervised Exercise and Counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use fo Antiseptic Solution for Vaginal Wash Before Cesarean Section in Patients With Premature Rupture of Membranes. A Randomized, Double Blind, Controlled Trial.
Brief Summary: To evaluate the rate of infections after cesarean sections in patients with premature rupture of membranes after vaginal wash either with an antiseptic solution (clorhexidine solution) vs. saline solution (placebo).


Options:
A: Arm Label: Clorhexidine; Type: EXPERIMENTAL; Interventions: Drug: Clorhexidine | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Intervention Type: DRUG; Name: Clorhexidine; Assigned to Arm(s): Clorhexidine | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): Saline solution
B: Arm Label: Chlorhexidine - Isopropyl alcohol; Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine - Isopropyl alcohol | Arm Label: Povidone-Iodine Scrub and Paint; Type: EXPERIMENTAL; Interventions: Drug: Povidone-Iodine Scrub and Paint | Intervention Type: DRUG; Name: Chlorhexidine - Isopropyl alcohol; Assigned to Arm(s): Chlorhexidine - Isopropyl alcohol | Intervention Type: DRUG; Name: Povidone-Iodine Scrub and Paint; Assigned to Arm(s): Povidone-Iodine Scrub and Paint
C: Arm Label: Chlorhexidine-alcohol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine-alcohol | Arm Label: Povidine-iodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Povidine-iodine | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile saline | Intervention Type: DRUG; Name: Chlorhexidine-alcohol; Assigned to Arm(s): Chlorhexidine-alcohol | Intervention Type: DRUG; Name: Povidine-iodine; Assigned to Arm(s): Povidine-iodine | Intervention Type: DRUG; Name: Sterile saline; Assigned to Arm(s): Saline
D: Arm Label: Abdominal and Vaginal Cleansing; Type: EXPERIMENTAL; Interventions: Procedure: Vaginal Cleansing, Procedure: Abdominal Cleansing | Arm Label: Abdominal Cleansing Alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal Cleansing | Intervention Type: PROCEDURE; Name: Vaginal Cleansing; Assigned to Arm(s): Abdominal and Vaginal Cleansing | Intervention Type: PROCEDURE; Name: Abdominal Cleansing; Assigned to Arm(s): Abdominal Cleansing Alone, Abdominal and Vaginal Cleansing

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Silver Diamine Fluoride Versus Therapeutic Sealants for the Arrest and Prevention of Dental Caries in Low-income Minority Children
Brief Summary: Dental caries (tooth decay) is the most prevalent childhood disease in the world. Multiple interventions are available to treat and prevent caries. The aim of the proposed study is to compare the benefit of silver diamine fluoride (SDF) and fluoride varnish versus fluoride varnish and glass ionomer sealants. This study is a five-year, cluster randomized, pragmatic controlled trial conducted in public elementary schools in New York City.


Options:
A: Arm Label: Simple Prevention; Type: EXPERIMENTAL; Interventions: Device: Silver Diamine Fluoride, Device: Fluoride Varnishes | Arm Label: Complex prevention; Type: ACTIVE_COMPARATOR; Interventions: Device: Fluoride Varnishes, Device: Glass Ionomer | Intervention Type: DEVICE; Name: Silver Diamine Fluoride; Assigned to Arm(s): Simple Prevention | Intervention Type: DEVICE; Name: Fluoride Varnishes; Assigned to Arm(s): Complex prevention, Simple Prevention | Intervention Type: DEVICE; Name: Glass Ionomer; Assigned to Arm(s): Complex prevention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Partial removal of carious dentine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Stepwise excavation | Intervention Type: PROCEDURE; Name: Partial removal of carious dentine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Stepwise excavation; Assigned to Arm(s): 2
C: Arm Label: Glass Ionomer Sealant; Type: EXPERIMENTAL; Interventions: Drug: Sealants to arrest microcavitated caries. | Arm Label: Resin Sealant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sealants to arrest microcavitated caries. | Intervention Type: DRUG; Name: Sealants to arrest microcavitated caries.; Assigned to Arm(s): Glass Ionomer Sealant, Resin Sealant
D: Arm Label: Hall Technique; Type: EXPERIMENTAL; Interventions: Procedure: Hall Technique | Arm Label: Non-Restorative Caries Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Non-Restorative Caries Treatment | Arm Label: Conventional Restoration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Restoration | Intervention Type: PROCEDURE; Name: Hall Technique; Assigned to Arm(s): Hall Technique | Intervention Type: PROCEDURE; Name: Non-Restorative Caries Treatment; Assigned to Arm(s): Non-Restorative Caries Treatment | Intervention Type: PROCEDURE; Name: Conventional Restoration; Assigned to Arm(s): Conventional Restoration

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Brief Summary: This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.


Options:
A: Arm Label: VX-659/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-659/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-659/TEZ/IVA; Assigned to Arm(s): VX-659/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-659/TEZ/IVA TC
B: Arm Label: JBT101 (lenabasum) 1 mg; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: JBT-101 (lenabasum) 5 mg; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: JBT-101 (lenabasum) 20 mg QD; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: JBT-101 (lenabasum) 20 mg BID; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: JBT-101 (lenabasum); Assigned to Arm(s): JBT-101 (lenabasum) 20 mg BID, JBT-101 (lenabasum) 20 mg QD, JBT-101 (lenabasum) 5 mg, JBT101 (lenabasum) 1 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Placebo BID
C: Arm Label: TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA
D: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Brief Summary: This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.


Options:
A: Arm Label: Ataluren (PTC124®); Type: EXPERIMENTAL; Interventions: Drug: Ataluren (PTC124®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren (PTC124®); Assigned to Arm(s): Ataluren (PTC124®) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA
C: Arm Label: VX-659/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-659/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-659/TEZ/IVA; Assigned to Arm(s): VX-659/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-659/TEZ/IVA
D: Arm Label: VX-659/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-659/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-659/TEZ/IVA; Assigned to Arm(s): VX-659/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-659/TEZ/IVA TC

Answer: D